⚖️ Files federal trademark or copyright suits

Celgene Corporation

Trademark enforcement profile · on record 1998–2023

Celgene Corporation has filed federal trademark or copyright enforcement actions. On record (1998–2023): 21 federal trademark or copyright lawsuits; 18 oppositions and cancellation petitions at the USPTO Trademark Trial and Appeal Board (prevailed in 64% of merits decisions).

Data summary based on public records (USPTO TTAB proceedings and PACER/CourtListener federal court dockets). Figures reflect filings on record, not a characterization of the merits or good faith of any individual action. Not legal advice.

Before you list

Selling anything that might resemble their marks?

Check your design against Celgene Corporation's registered marks — and 13M+ others — before you list.

Check your design free

Free trial · no card · 3 checks that never expire

Federal court filings

0
Schedule-A cases
naming online sellers as defendants
20
Federal trademark cases
nature-of-suit 840
1
Federal copyright cases
nature-of-suit 820

At the Trademark Trial and Appeal Board (TTAB)

14
Oppositions
under 15 U.S.C. §1063
4
Cancellation petitions
under 15 U.S.C. §1064
7
Prevailed
on the merits, by default, or by abandonment
4
Did not prevail
adverse ruling on the merits
7
Settled / withdrawn
ended without a Board ruling on the merits

Prevailed in 64% of proceedings the Board actually decided on the merits (settled and withdrawn proceedings excluded from this calculation).

Designs Celgene Corporation has opposed

Real trademark applications Celgene Corporation challenged at the USPTO — the kind of design that draws an opposition. If your artwork looks like one of these, expect pushback. Each links to its USPTO docket.

Source: USPTO Trademark Trial and Appeal Board records. “Prevailed” means Celgene Corporation got the outcome it sought; settled/withdrawn cases ended without a Board ruling on the merits. Images from public USPTO records.

Marks Celgene Corporation has asserted in proceedings

CELGENE
CELGENE
asserted in 2 proceedings
REVLIMID
REVLIMID
asserted in 1 proceedings
REFLECTIONS A PATIENT AND CAREGIVER AMBASSADOR PRO
REFLECTIONS A PATIENT AND CAREGIVER AMBASSADOR PRO
asserted in 1 proceedings
A ABRAXIS BIOSCIENCE
A ABRAXIS BIOSCIENCE
asserted in 1 proceedings
ABRAXIS ONCOLOGY
ABRAXIS ONCOLOGY
asserted in 1 proceedings
ABRAXIS ONCOLOGY
ABRAXIS ONCOLOGY
asserted in 1 proceedings
ABRAXIS ONCOLOGY
ABRAXIS ONCOLOGY
asserted in 1 proceedings
ABRAXIS PHARMACEUTICAL PRODUCTS
ABRAXIS PHARMACEUTICAL PRODUCTS
asserted in 1 proceedings
MarkSerialProceedings
CELGENEtext752283844
S.T.E.P.S.text760193993
CELGENE752281282
UNVEILtext865237131
MYPRO FOR MULTIPLE MYELOMAtext883187181
PPM PLEIOTROPIC PATHWAY MODIFIERtext866415051
REVtext784024921
REVLIMIDtext781884501
REVLIMIDtext782905831
REVLIMID766313011
REVLIMIDtext787959421
REFLECTIONS A PATIENT AND CAREGIVER AMBASSADOR PRO871881551
IMIDtext770124321
MYPRO FOR MMtext883187701
ABRAXIStext783346001
ABRAXIStext788571971
ABRAXIS RESEARCHtext788571881
ABRAXIS BIOSCIENCEtext788007901
A ABRAXIS BIOSCIENCE788650061
ABRAXIS ONCOLOGYtext788665331
ABRAXIS ONCOLOGY789807281
ABRAXIS ONCOLOGY788650421
ABRAXIS ONCOLOGY784165231
ABRAXIS ONCOLOGY RESOURCE CENTERtext788889541
ABRAXIS PHARMACEUTICAL PRODUCTStext788572031
ABRAXIS PHARMACEUTICAL PRODUCTS788650631
ABRAXIS HEALTH779450231
ABRAXIS BIOSENSORStext851355371
PLACENTA CORDtext789516691
REBLOZYLtext873299591
REBLOZYL888227441
REBLOZYL900335231
PLEIOTROPIC PATHWAY MODIFIERtext866414821
VIDAZAtext781383241
AMNIOTIC MEMBRANE DERIVED ADHERENT CELLStext774440101
CELGENEtext765151161
SELCIDStext760257201
MYPROtext883189641

From public USPTO records. A mark is listed when it appears as a senior asserted mark in TTAB or federal-court proceedings on file. Serial links open the USPTO TSDR record.

Selling a design that may resemble Celgene Corporation’s registered marks?

Run a visual similarity check against Celgene Corporation’s registered marks — and 13M+ other USPTO trademark images — before you list. Takes about 10 seconds.

Run a free visual check

FAQ

Data sources: publicly published USPTO Trademark Trial and Appeal Board proceedings (1951–2026, with possible gaps before electronic filing) and U.S. federal court dockets (PACER/CourtListener, nature-of-suit codes 840 and 820). Figures reflect filings on record and do not characterize the merits, validity, or legitimacy of any individual action by Celgene Corporation. Trademark holders have legal rights — and in some doctrines, an obligation — to enforce registered marks. This page does not provide legal advice; consult licensed counsel for case-specific questions. See the full leaderboard.